Exclusive-Major Novartis shareholder calls for board shake-up after drug trial setbacks

A major shareholder of Novartis is demanding a significant shake-up of the company board. This call for leadership changes follows a series of setbacks related to drug trials. The investor is pushing for structural adjustments within the governance of the pharmaceutical giant to address the recent failures in clinical developments. The situation highlights growing pressure from key stakeholders regarding the strategic direction and oversight of Novartis following these disappointing results in their drug trial pipeline.